Fwd: [NREN-Community] Fwd: [Sci-GaIA.Consortium] URGENT - Call for a PhD position in the context of an International Training Network

[héritier mapela]

---------- Forwarded message ----------
From: augustin kanyimbu <augustin...@unikin.ac.cd>
Date: Thu, 13 Apr 2017 12:33:49 +0100
Subject: Fwd: [NREN-Community] Fwd: [Sci-GaIA.Consortium] URGENT -
Call for a PhD position in the context of an International Training
Network
To: News <info....@unikin.ac.cd>

Mesdames,
Messieurs,

je vous prie de trouver ci-dessous une grande opportunité de financement de
recherche de niveau doctorale en ICT, pour ceux que ça pourrait intéresser,
et n'hésitez pas à passer l'information à qui pourrait être concerné.

Bien à vous,
Augustin K
---------------------------------------------------------------------------
KANYIMBU MUTOMBO Augustin
IT Manager
+243 998124376
+243 848420937 | <Augustin...@unikin.ac.cd>
augustin...@unikin.ac.cd
| University of Kinshasa
| DRC, Kinshasa

---------- Forwarded message ----------
From: Tiwonge Banda <tiwong...@ubuntunet.net>
Date: 2017-04-12 20:17 GMT+01:00
Subject: [NREN-Community] Fwd: [Sci-GaIA.Consortium] URGENT - Call for a
PhD position in the context of an International Training Network
To: nren-co...@lists.ubuntunet.net


Dear Colleagues,
Here is an opportunity below that you or someone you know may be
interested.’

Best wishes,
Tiwonge
--
Tiwonge Msulira Banda
F&A Manager, UbuntuNet Alliance
P.O. Box 2550, Lilongwe, Malawi
Web: www.ubuntunet.net | Follow us on Twitter @ubuntunet
<http://www.twitter.com/ubuntunet>

Tel/Fax: +265 17 54535 | Mobile: +265 99 93 40740 | Alt email:
tiwo...@gmail.com

Begin forwarded message:

*From: *"Roberto Barbera" <roberto...@ct.infn.it>
*Subject: **[Sci-GaIA.Consortium] URGENT - Call for a PhD position in the
context of an International Training Network*
*Date: *12 April 2017 at 11:36:09 AM GMT-4
*To: *<conso...@sci-gaia.eu>

Dear All,

Please find below an interesting call for a PhD position in Italy. The
deadline to apply is the *19th of April*.

Ciao

Roberto

------------------------------------------------------------
------------------------------------------------------------
------------------------

Dear distinguished Colleagues,

I apologize for a possible cross-posting of this message.

I am looking for bright young graduated from university with the requisites
to apply for a position of *early stage researcher (ERS) *within an Italian
doctorate (namely the Doctorate School of Clinical and Experimental
Neurosciences and Psychiatry at the Sapienza University of Rome, Italy).
This *early stage researcher* may be an extraordinary opportunity for our
scientific cooperation in the field of innovative information and
communication technology (ICT) applied to the analysis and visualization of
biomarkers of Alzheimer’s disease (AD). He or she is expected to work for
an expansion of the services (e.g. data upload, management, processing, and
integration, etc.) of the ICT platform of Italian GARR, namely the DECIDE
platform originally developed in the framework of the FP7 ICT
Infrastructure “DECIDE”
https://www.eu-decide.eu <https://www.eu-decide.eu/?jjj=1490809431516>.

The application of the *early stage researcher *should be sent by 19th of
April 2017 (h 12.00 noon, CET) following the instructions reported at
http://dff.uniroma1.it/it/node/6092
The interview is planned for 15th of May 2017 (via skype).
The result of the evaluation process will be communicated on 19th of May
2017.
The position will be available immediately with expected start date on 1st of
June 2017. It will last 36 months with guaranteed funding from

*Horizon 2020, Call:* H2020-MSCA-ITN-2016 (Marie Skłodowska-Curie
Innovative Training Networks)
*Type of action:* MSCA-ITN-ETN (European Training Networks) Project number:
721281
*Project title:* Blood Biomarker-based Diagnostic Tools for Early-stage
Alzheimer’s Disease
*Project acronym:* BBDiag
*Duration of the project:* 48 months (start date of 1st of January 2017)
http://cordis.europa.eu/project/rcn/205430_en.html

The *early stage researcher *will have to spend *24 months* based at the
Department of Physiology and Pharmacology “Erspamer”, Sapienza University
of Rome (Italy), and Consortium GARR of Rome. Furthermore, he or she will
have to spend 12 months in top academic and industrial Partners of the
BBDiag Consortium.

Specifically, the candidate winning the public competition in the object
(local Academic Committee) will be involved in the activities for reaching
the following BBDiag project objectives:

1) To develop plug-in interfaces in the DECIDE platform to store and
retrieve data coming from devices settled during the BBDiag project for
subject’s telemonitoring from the resident home (e.g. graphene PoC tools
and ELISA barcoding arrays & telomere sensors);

2) To expand the DECIDE big data techniques and algorithms to manage,
process, and integrate information collected from the mentioned BBDiag
devices and those matured in previous trials (e.g. electroencephalographic
biomarkers of AD, cognitive-motor performances, and lifestyle indexes).

The general aim of the *early stage researcher*’s activities is to explore
and develop innovative ICT-based services for the prevention, early
diagnosis, and telemonitoring of pathological aging with a focus on AD. In
the DECIDE platform, the Sapienza University Unit will collect big amount
of heterogeneous data in AD and Parkinson’s disease (PD) such as
traditional numeric markers from neuroimaging and electroencephalographic
data, files of measures made of analytical parameters (traditional discrete
data), graphic objects, images, questionnaires, cognitive-motor
performances, lifestyle indexes, etc. In this context, the *early stage
researcher* will receive an initial interdisciplinary training on the
DECIDE platform and medical devices integrated in ICT healthcare platforms.
Afterward, he/she will be involved in the development of the new DECIDE
plug-in interfaces and data analysis algorithms.

Skills/Qualifications of extreme interest:
previous experience with the ICT-based services;
interest in the research on the biomarkers of Alzheimer’s disease
.
As important pre-requisites,

- The candidate will have to have resided for 24 months outside from Italy
in the last 36 months before the 6th of March 2017.
- He/she should be not enrolled in a PhD course;
- He/she should have obtained the Master of Science no more than 4 years
before the 6th of March 2017.

Please pass this onto anyone who may be interested & qualified. The
position description is pasted below in more details.

Thanks in advance.

Best regards,

Fulvio Galeazzi, Ph.D.
Consortium GARR
Via dei Tizii, 6, 00185, Rome, Italy
http://www.garr.it
Phone/Fax: 0039 0649622542/2044
Email: fulvio....@garr.it

And

Claudio Babiloni, Ph.D.
Department of Physiology and Pharmacology "V. Erspamer"
University of Rome "La Sapienza" (UNROMA1)
P.le A. Moro 5, 00185, Rome, Italy
Phone/Fax: 0039 0649910989 <+39%2006%204991%200989>/0917
Skype: claudio.babiloni
Email: claudio....@uniroma1.it


*Descriptors of the BBDiag project: *Diagnostic and implantable devices,
environmental monitoring; Neurological disorders (e.g. Alzheimer's
disease); Sensor networks, embedded systems, hardware platform; Scientific
computing and data processing; Public economics.

*Keywords:* Diagnostics of early-stage Alzheimer's disease, blood AD
biomarkers, biosensors, electronics, preclinical, validation, clinical,
trials, machine learning, business.

*Abstract of the BBDiag project:*
Alzheimer’s disease (AD) affects more than 7 million people in Europe, and
this figure is expected to double every 20 years. Despite intensive
efforts, no disease-modifying treatments or preventive strategies are
available. The lack of specific, sensitive and minimally invasive
diagnostics to identify people with early-stage AD to be included in
clinical drug intervention trials is among the main reasons for many
notable trial failures. The main challenges in developing the required
diagnostics are the identification of AD biomarkers and development of
their detection techniques. The complex and interdisciplinary nature of the
research underlines the need for innovative training of a new generation of
researchers in the field. BBDiag responds to such a need and establishes a
much-needed ETN for blood-based early-AD diagnostics to address these
challenges. It brings together leading academic and industrial experts from
five major consortia in Europe and uses their synergies to build a triple-i
research & training platform with the required multidisciplinary expertise
and cutting-edge technologies. BBDiag Fellows will be trained under the
Vitae Researcher Development Framework innovatively combined with the
BBDiag platform for gaining interdisciplinary scientific and transferable
skills as well as personal quality, creative thinking, and business
mindset. The ETN has a highly innovative research programme for the
discovery of AD biomarkers, development of novel biosensing techniques and
point of care tools, and for technological exploitation of the diagnostics.
These advances will strongly support improved care provision and
development of disease-modifying treatments and preventive strategies for
AD patients. More importantly, BBDiag will deliver its first generation of
13 highly-skilled, creative and entrepreneurial Fellows, setting them on a
path to successful careers in academia or industry to ensure that the
medical and societal challenges imposed by AD are met.

*More details on the BBDiag project:*
The identification of early stages of AD (prodromal and mild dementia),
before the onset of massive, irreversible neuronal loss and cognitive
decline, is a key requirement for the development of disease-modifying
treatments and preventive strategies. Established techniques based on
cerebrospinal fluid (CSF) protein biomarkers and neuroimaging (MRI, PET)
can provide a diagnosis of AD at clinically manifest stages and support the
diagnostics of early-stage AD. In both cases, the large-scale use of CSF
and imaging markers is limited by quite invasive protocols and the need for
high-cost instruments. Highly sensitive blood biomarkers can be useful as
entry diagnostic tests, or gate-keeping screens, to identify patients with
early-stage AD for more invasive and expensive biomarker testing using
imaging or CSF. If further refined, blood-based biomarkers with sufficient
sensitivity and specificity could even become diagnostic markers to replace
more expensive CSF sampling or imaging, and add accuracy in identifying
comorbidities. Recent advances in the discovery of blood-based biomarkers
for early pathological changes of AD2, and in developing nanomaterial-based
highly sensitive biosensors have shown the potential to develop blood
biomarker-based diagnostic tools for early-stage AD with the desirable
features of minimally invasive, highly sensitive and inexpensive. However,
to turn these promising developments into a clinically applicable
diagnostic tool requires further joint interdisciplinary research efforts
involving a large number of disciplines including neurobiology, disease
pathogenesis, biology, high-level computation and data mining,
biotechnology, electronics, materials, physics, nano-biosensing,
preclinical and clinical testing and evaluation, and business and
entrepreneurship. The complex and interdisciplinary nature of the research
underlines the need for innovative training of a new generation of
highly-skilled, creative, entrepreneurial and innovative researchers.
BBDiag responds to such a need and timely sets up an ETN with the required
interdisciplinary expertise and cutting-edge technologies to provide a
high-quality triple-i (interdisciplinary, intersectoral and international)
research platform for the training of a new generation of early-stage
researchers (ESRs) for the development of such an important diagnostic
technology. Our consortium consists mainly of leading academic and
industrial experts drawn from 5 major consortia across Europe with
expertise in AD blood biomarkers (The International Blood-Based Biomarker
Interest Group), preclinical & clinical validation and trials (FP7 &
Alzheimer Europe PharmaCog), and biosensing & AD (FP7-NADINE, UK - Sensing
for Dementia and H2020 Graphene Flagship). These experts will bring to the
ETN the state-of-the-art of their respective consortia to provide the core
multidisciplinary expertise of the network. Additional high-quality
academic, industrial and international partners are also brought into the
consortium to strengthen the ETN in its triple-i dimensions, cutting-edge
technology, entrepreneurship. Concerning the triple-i dimension of the
consortium, the ETN involves seven academic, six non-academic and two
international Institutions, whose expertise spans across five major
scientific disciplines (Life science, Engineering, Physical science,
Healthcare, and Economics). Six non-academic institutions (4 companies) are
involved in the ETN demonstrating the strong cross-sectoral (public &
private sectors) participation and contribution to the research and
training programme.

*The main Training objectives (TO) of the ETN:*
TO1. To set up a multidisciplinary ETN for the training of ESRs for blood
biomarker-based diagnostics for early stage AD with four main training
features: discovery & innovation, “triple-i” research & training,
entrepreneurship, and skills set for future leaders (see page 3 for
detail).
TO2. To rigorously train the Fellows for domain-specific knowledge, skills
and hands-on experience by the provision of cross-disciplinary/cross-sectoral
supervision teams complemented with personal mentoring to make them highly
competent in achieving the scientific objectives (SOs) of the project (see
pages 2-3). To empower the Fellows to be the leading experts in their
respective fields by placing them at the forefront of the scientific
challenges with opportunities to make advances to take their fields beyond
the current state-of-the-art.
TO3. To provide extensive training for all Fellows to attain the
fundamental interdisciplinary knowledge and skills for the whole BBDiag
field spanning across engineering, physical science, life science,
healthcare & business, to ensure that the Fellows are true polymaths able
to meet their future career challenges.
TO4. To provide specialized network training on entrepreneurship covering
all aspects of the innovation process, coupled with extensive secondment
opportunities with industrial, clinical and international partners to
develop Fellow’s innovative thinking and business mind-set.
TO5. To train the Fellows to develop a complete set of transferable
knowledge, skills and behavior of world-class researchers by a series of
local, work-package based and network-wide training events, specially
designed under the Vitae Researcher Development Framework (Vitae RDF) - an
innovative researcher training model endorsed by the UK Joint Research
Council.
The research & training platform spans across four scientific themes:
Biosensing & PoC devices, AD biomarker discovery, Validation and trials,
and Exploitation & entrepreneurship. The strong interaction and integration
across the four scientific themes are crucial to the training through
research and to the central RTD goal of the ETN, i.e., the development of
blood biomarker-based diagnostic tools for early-stage AD.

*The scientific objectives (SO) of the BBDiag project: *
SO1. To develop novel graphene and ELISA barcoding based multiplexed
biosensing techniques with embedded electronics for the detection of a
panel of blood-based AD biomarkers at clinically relevant concentrations.
SO2. To discover a panel of most reliable early-AD blood biomarkers by
employing innovative techniques.
SO3. To develop a fully integrated prototype point of care (PoC)
diagnostic tool for early-stage AD.
SO4. To carry out preclinical and clinical validation for assessment
of reliability & pathologies of biomarkers.
SO5. To carry out clinical trials for evaluation of diagnostic
accuracy of the BBDiag PoC tool.
SO6. To develop an innovative business model and exploitation
strategies for early-AD diagnostics, and to explore novel commercial and
clinical applications of the technology.

*The main features of the training programme: *
• Discovery & innovation: The scientific excellence of the ETN
is characterized by “discovery & innovation”. The project identifies the
main scientific challenges for developing blood-based AD diagnostics and
proposes innovative approaches to address these challenges. It aims at the
discovery of blood-based AD biomarkers and cutting-edge technological
innovations in biosensing, AD diagnostic tools, ICT healthcare platforms
and big data AD diagnostics, clinical trials, and business modeling for
early-stage AD diagnosis. This presents an excellent multidisciplinary
research platform for the Fellows to be trained through research to gain
interdisciplinary knowledge, expertise, and skills. They will have the
opportunities to make scientific advances to take their own respective
fields beyond the current state-of-the-art and empower them to be the
leading experts in this emerging field (linked to TO1 and SOs1-5).
• “Triple-i” research & training Interdisciplinary is the
nature and also one of the challenges in the development of blood-based AD
diagnostics as the research spans across a wide range of disciplines. This
underlines the need for the training of interdisciplinary knowledge and
skills for a new generation of Fellows. The ITN aims to make its Fellows
true polymaths – having a specialty with high expertise in one
subject-discipline (linked to TO2) and also the capacity to engage
technically/intellectually with cross-disciplinary fellows in life science,
engineering, physical science, clinicians and regulators of this emerging
field (linked to TO3). The inter-sectoral research and training experience
of our fellows will be achieved by contributions from the 5 industrial
beneficiaries and 2 nonacademic partners in the form of co-supervision,
network training events, secondments and hosting of 5 ESRs. Two
international partners are leading institutions in China and will
contribute to secondments, co-supervision and network training in
biosensing and AD clinics and trials (linked to TO4).
• Entrepreneurship: The ETN has involved the participation of
Beneficiaries from two companies and one academia in Business Studies,
supported by an industrial partner in IP enterprising, to provide a
platform for the Fellows to interact with business leaders of the field for
developing their entrepreneurship skills and mind-set. This is further
enhanced with additional network entrepreneurship training and secondments
in the 6 non-academic Beneficiaries/partners (linked to TO4).
• Skills set for future leaders: The skills set is
tailor-designed under the innovative Vitae RDF in conjunction with the
BBDiag triple-i research & training platform, across the four Vitae
domains: Knowledge & intellectual ability, Personal effectiveness and
professional conduct, Research governance and organization, and Engagement,
influence and impact, for the training of a complete set of skills,
attributes and mind-sets for a new generation of highly-skilled, talented,
creative, & entrepreneurial ESRs. This is complemented with the
implementation of a Vitae self-assessment facility for regular monitoring
of the training progress of each ESR and a personalized Vitae Career
Development Planner (CDP) for helping the Fellows to maximize their
potential and get the most out of their careers. (linked to TO5).
SRs in these different and new environments will also present challenges
for them to learn new knowledge and skills outside their comfort zone and
to develop the ability to make imaginative leaps of understanding across
disciplines/ research areas/ agendas and beyond academia.


--
Department of Physics and Astronomy of the University of Catania
Phone : +39 095 378 5504 <+39%20095%20378%205504>
Mobile: +39 349 376 2671 <+39%20349%20376%202671>
Fax : +39 095 337 938
eMail : roberto...@ct.infn.it
Web : http://www.dfa.unict.it/docenti/roberto.barbera
ORCID : http://orcid.org/0000-0001-5971-6415

_______________________________________________
Sci-gaia.consortium mailing list
Sci-gaia....@sci-gaia.eu
https://mailman.ct.infn.it/mailman/listinfo/sci-gaia.consortium



_______________________________________________
nren-community mailing list
nren-co...@lists.ubuntunet.net
http://lists.ubuntunet.net/listinfo/nren-community



--
Sincerely,

MAPELA BAKA Heritier.
IT SMSI Specialist
Mobile : +243 859 094 161
Skype : hmapela

[jobndambi]

Hi guy; 

C est comme si vs avez oublié d attaché le fichier svp.

Reprend l envoi svp.

Regards.

Envoyé depuis mon appareil Samsung

-------- Message d'origine --------
De : héritier mapela <hmap...@gmail.com>
Date : 13/04/2017 1:03 PM (GMT+01:00)
À : mathinfounikin2009 <mathinfou...@googlegroups.com>
Objet : Fwd: [NREN-Community] Fwd: [Sci-GaIA.Consortium] URGENT - Call for a PhD position in the context of an International Training Network

--

---
Vous recevez ce message, car vous êtes abonné au groupe Google Groupes math-info unikin Promotion 2009.
Pour vous désabonner de ce groupe et ne plus recevoir d'e-mails le concernant, envoyez un e-mail à l'adresse mathinfounikin2...@googlegroups.com.
Pour plus d'options, visitez le site https://groups.google.com/d/optout .

[héritier mapela]

Salut Job,
Je n'ai fait que transférer le mail tel que reçu. Il n'y a donc pas de
fichier joint à ce message si ce n'est le contenu explicatif repris
en dessous de ce dont l'objet est susmentionné.
Cordialement.

2017-04-13 13:03 UTC+01:00, héritier mapela <hmap...@gmail.com>:

[André Luma]

Merci beaucoup mon Frère!

--

---
Vous recevez ce message, car vous êtes abonné au groupe Google Groupes math-info unikin Promotion 2009.
Pour vous désabonner de ce groupe et ne plus recevoir d'e-mails le concernant, envoyez un e-mail à l'adresse mathinfounikin2...@googlegroups.com.
Pour plus d'options, visitez le site https://groups.google.com/d/optout .

--
Envoyé avec Gmail Mobile

[jobndambi]

O

Envoyé depuis mon appareil Samsung

-------- Message d'origine --------
De : héritier mapela <hmap...@gmail.com>

Date : 14/04/2017 8:46 AM (GMT+01:00)
À : mathinfounikin2009 <mathinfou...@googlegroups.com>
Objet : Re: [NREN-Community] Fwd: [Sci-GaIA.Consortium] URGENT - Call for a PhD position in the context of an International Training Network